Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes

References

• FarberHWLoscalzoJPulmonary arterial hypertensionN Engl J Med2004351161655166515483284
   PubMed Web of Science ®Google Scholar
• GalieNRubinLHoeperMTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialLancet200837196302093210018572079
   PubMed Web of Science ®Google Scholar
• GalieNBarberaJAFrostAEInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionN Engl J Med2015373983484426308684
   PubMed Web of Science ®Google Scholar
• McLaughlinVChannickRNGhofraniHABosentan added to sildenafil therapy in patients with pulmonary arterial hypertensionEur Respir J201546240541326113687
   PubMed Web of Science ®Google Scholar
• Selexipag (Uptravi) for pulmonary arterial hypertensionMed Lett Drugs Ther2016581488212326859660
   PubMed Web of Science ®Google Scholar
• PulidoTAdzerikhoIChannickRNSERAPHIN InvestigatorsMacitentan and morbidity and mortality in pulmonary arterial hypertensionN Engl J Med2013369980981823984728
   PubMed Web of Science ®Google Scholar
• SitbonOChannickRChinKMSelexipag for the treatment of pulmonary arterial hypertensionN Engl J Med2015373262522253326699168
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid ServicesNational Health Expenditure Data: Projected2017 Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsProjected.htmlAccessed August 24, 2017
   Google Scholar
• Express ScriptsDrug Trend Report 2016: Express Scripts2016 Available from: https://lab.express-scripts.com/lab/drug-trend-reportAccessed Aug 24, 2017
   Google Scholar
• McLaughlinVVArcherSLBadeschDBACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationJ Am Coll Cardiol200953171573161919389575
   PubMed Web of Science ®Google Scholar
• GalieNHumbertMVachieryJL2015ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)Eur Heart J20163716711926320113
   PubMed Web of Science ®Google Scholar
• SimonneauGGatzoulisMAAdatiaIUpdated clinical classification of pulmonary hypertensionJ Am Coll Cardiol201362(25 Suppl):D34D4124355639
   PubMed Web of Science ®Google Scholar
• HuismanAMVreugdenhilSAvan PaassenHCTreatment of pulmonary arterial hypertensionN Engl J Med20053523308309 author reply 308–30915659740
   PubMed Web of Science ®Google Scholar
• EnderbyCYBurgerCMedical treatment update on pulmonary arterial hypertensionTher Adv Chronic Dis20156526427226336595
   PubMed Web of Science ®Google Scholar
• HoeperMMMcLaughlinVVBarberaJAInitial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION studyLancet Respir Med201641189490127745818
   PubMed Web of Science ®Google Scholar
• GalieNJansaPPulidoTSERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionEur Heart J201738151147115528329315
   PubMed Web of Science ®Google Scholar
• BrudererSHurstNRemenovaTDingemanseJClinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertensionExpert Opin Drug Saf201716674375128494686
   PubMed Web of Science ®Google Scholar
• GhofraniHAGalieNGrimmingerFRiociguat for the treatment of pulmonary arterial hypertensionN Engl J Med2013369433034023883378
   PubMed Web of Science ®Google Scholar
• CoghlanJGGalieNBarberaJAInitial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trialAnn Rheum Dis20177671219122728039187
   PubMed Web of Science ®Google Scholar
• ChannickRNDelcroixMGhofraniHAEffect of macitentan on hospitalizations: results from the SERAPHIN trialJACC Heart Fail2015311825457902
   PubMed Web of Science ®Google Scholar
• LiuHLChenXYLiJREfficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trialsChest2016150235336627048870
   PubMed Web of Science ®Google Scholar
• LajoieACLauziereGLegaJCCombination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysisLancet Respir Med20164429130526935844
   PubMed Web of Science ®Google Scholar
• JainSKheraRGirotraSComparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysisChest201715119010527615023
   PubMed Web of Science ®Google Scholar
• BenzaRLMillerDPGomberg-MaitlandMPredicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)Circulation2010122216417220585012
   PubMed Web of Science ®Google Scholar
• BenzaRLGomberg-MaitlandMMillerDPThe REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertensionChest2012141235436221680644
   PubMed Web of Science ®Google Scholar
• BurgerCDOzbayBRiehleELenhartGWhiteRJTreatment Patterns After Initial Therapy Among Pulmonary Arterial Hypertension Patients In The United States [Abstract]Am J Respir Crit Care Med2016193A3987
   Google Scholar
• BurgerCDLongPKShahMRCharacterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registryChest201414651263127324901386
   PubMed Web of Science ®Google Scholar
• FrantzRPSchilzRJChakinalaMMHospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational studyChest2015147248449425320967
   PubMed Web of Science ®Google Scholar
• BurkeJPHunscheERegulierENagaoMBuzinecPDrake IiiWCharacterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database studyAm J Manag Care2015213 Suppls47s5825734573
   PubMed Web of Science ®Google Scholar
• Medicare Payment Advisory Commission USDOH, Human SMedicare Payment Advisory Commission report to the Congress, March 2010J Pain Palliat Care Pharmacother201024330230520718654
   PubMedGoogle Scholar
• PopaABosentan (Tracleer), a New Agent for the Treatment of Pulmonary Arterial HypertensionPharmacotherapy Update2002V(2).
   Google Scholar
• SikiricaMIorgaSRBancroftTPotashJThe economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patientsBMC Health Serv Res20141467625539602
   PubMed Web of Science ®Google Scholar
• GuSHuHDongHSystematic Review of the economic burden of pulmonary arterial hypertensionPharmacoeconomics201634653355026714685
   PubMed Web of Science ®Google Scholar
• JohnsonSDelateTBokaAShawPZagerCCharacterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery systemJ Med Econ201316121414142224074226
   PubMedGoogle Scholar
• OudizRJMathaiSWhiteRJacobsenMWeyckerDBurgerCCost consequences of initial combination treatment of pah with ambrisentan and tadalafilAm J Respir Crit Care Med2016193A2953
   Web of Science ®Google Scholar
• BeaudetATsangYHunscheEDrakeWBilirSPBudget impact model for selexipag: taking a US payer perspectiveValue Health2016193A243A244
   Web of Science ®Google Scholar
• LiHHighlandKColeMMinimizing burden of disease-related hospitalization among pulmonary arterial hypertension patients [Abstract]J Manag Care Spec Pharm20162210-a SupplS57
   Google Scholar
• BergerAEdelsbergJTealSMychaskiwMAOsterGChanges in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort studyBMC Pulm Med2012127523231890
   PubMed Web of Science ®Google Scholar
• VaidyaBGuptaVNovel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug deliveryJ Control Release201521111813326036906
   PubMed Web of Science ®Google Scholar
• GeraciMWBullTMTuderRMGenomics of pulmonary arterial hypertension: implications for therapyHeart Fail Clin20106110111419945066
   PubMedGoogle Scholar
• KjellstromBFrantzRPBenzaRLBennettTBourgeRCMcGoonMDHemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertensionJ Card Fail201420748549124816520
   PubMed Web of Science ®Google Scholar